120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
SGLT2抑制剂治疗抑郁症的潜在作用：机制与临床前景
Authors Cheng H, Jing Y, Xu C, Chen M , Su H, Yang X , Zhang L
Received 16 September 2025
Accepted for publication 31 December 2025
Published 22 January 2026 Volume 2026:20 567851
DOI https://doi.org/10.2147/DDDT.S567851
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Solomon Tadesse Zeleke
Hanyao Cheng,1– 3 Yao Jing,4 Changjing Xu,2,3 Maolin Chen,2,3 Hao Su,2,3 Xuping Yang,2 Liaoyun Zhang1
1Department of Pharmacy, Sichuan Provincial Maternity and Child Health Care Hospital, Chengdu, Sichuan, People’s Republic of China; 2Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China; 3School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, People’s Republic of China; 4Department of Nursing, The First People’s Hospital of Changde City, Changde, Hunan, People’s Republic of China
Correspondence: Liaoyun Zhang, Department of Pharmacy, Sichuan Provincial Maternity and Child Health Care Hospital, Chengdu, Sichuan, People’s Republic of China, Email zhangliaoyun1984@163.com Xuping Yang, Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China, Email yangxuping6552@163.com
Abstract: Major depressive disorder (MDD) is a high-burden psychiatric illness characterized by persistent low mood, diminished interest, and cognitive impairment. Its global prevalence continues to rise, accompanied by a significant risk of suicide. Traditional first-line treatments, such as selective serotonin reuptake inhibitors (SSRIs), are limited by delayed onset, limited response rates, and adverse effects, which has spurred the exploration of novel therapeutic strategies. A growing body of research indicates that the pathogenesis of MDD extends beyond the monoamine hypothesis, also involving neuroinflammation, oxidative stress, hypothalamic-pituitary-adrenal (HPA) axis dysfunction, and cerebral energy metabolism impairment. Notably, there is a well-established bidirectional association between MDD and type 2 diabetes (T2DM), with the prevalence of depression nearly doubling among diabetic patients. The pathological processes shared by both conditions include insulin resistance, oxidative stress caused by chronic hyperglycemia, accumulation of advanced glycation end products (AGEs), persistent low-grade inflammation, and overactivation of the HPA axis. These mechanisms work synergistically to promote neuronal damage and emotional dysregulation. In recent years, sodium–glucose cotransporter 2 inhibitor (SGLT2i) have emerged as a novel therapeutic direction with dual “metabolic-neural” regulatory potential, as they may intervene in multiple key pathways central to the comorbidity of MDD and T2DM by mitigating neuroinflammation and oxidative stress, inhibiting apoptosis, and enhancing synaptic plasticity. Although evidence for their application in the psychiatric field remains in its early stages, current preclinical and observational studies have already demonstrated significant potential. It is important to emphasize that SGLT2i may still cause adverse effects such as sleep disturbances and anxiety, requiring cautious evaluation in psychiatric applications. Additionally, there is still a significant lack of prospective randomized controlled trials with depression improvement as the primary endpoint, and their true antidepressant efficacy and safety await further validation. This review discusses their therapeutic potential and provides a foundation for developing comprehensive treatment strategies for patients with comorbid MDD and T2DM.
Keywords: SGLT2i, depression, type 2 diabetes mellitus, neuroprotection, oxidative stress
1Department of Pharmacy, Sichuan Provincial Maternity and Child Health Care Hospital, Chengdu, Sichuan, People’s Republic of China; 2Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China; 3School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, People’s Republic of China; 4Department of Nursing, The First People’s Hospital of Changde City, Changde, Hunan, People’s Republic of China
Correspondence: Liaoyun Zhang, Department of Pharmacy, Sichuan Provincial Maternity and Child Health Care Hospital, Chengdu, Sichuan, People’s Republic of China, Email zhangliaoyun1984@163.com Xuping Yang, Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China, Email yangxuping6552@163.com
Abstract: Major depressive disorder (MDD) is a high-burden psychiatric illness characterized by persistent low mood, diminished interest, and cognitive impairment. Its global prevalence continues to rise, accompanied by a significant risk of suicide. Traditional first-line treatments, such as selective serotonin reuptake inhibitors (SSRIs), are limited by delayed onset, limited response rates, and adverse effects, which has spurred the exploration of novel therapeutic strategies. A growing body of research indicates that the pathogenesis of MDD extends beyond the monoamine hypothesis, also involving neuroinflammation, oxidative stress, hypothalamic-pituitary-adrenal (HPA) axis dysfunction, and cerebral energy metabolism impairment. Notably, there is a well-established bidirectional association between MDD and type 2 diabetes (T2DM), with the prevalence of depression nearly doubling among diabetic patients. The pathological processes shared by both conditions include insulin resistance, oxidative stress caused by chronic hyperglycemia, accumulation of advanced glycation end products (AGEs), persistent low-grade inflammation, and overactivation of the HPA axis. These mechanisms work synergistically to promote neuronal damage and emotional dysregulation. In recent years, sodium–glucose cotransporter 2 inhibitor (SGLT2i) have emerged as a novel therapeutic direction with dual “metabolic-neural” regulatory potential, as they may intervene in multiple key pathways central to the comorbidity of MDD and T2DM by mitigating neuroinflammation and oxidative stress, inhibiting apoptosis, and enhancing synaptic plasticity. Although evidence for their application in the psychiatric field remains in its early stages, current preclinical and observational studies have already demonstrated significant potential. It is important to emphasize that SGLT2i may still cause adverse effects such as sleep disturbances and anxiety, requiring cautious evaluation in psychiatric applications. Additionally, there is still a significant lack of prospective randomized controlled trials with depression improvement as the primary endpoint, and their true antidepressant efficacy and safety await further validation. This review discusses their therapeutic potential and provides a foundation for developing comprehensive treatment strategies for patients with comorbid MDD and T2DM.
Keywords: SGLT2i, depression, type 2 diabetes mellitus, neuroprotection, oxidative stress